Radicava (edaravone)
NO BOXED WARNING
Dosage & Administration
Get Your Patient on Radicava
See your patient's specific prior authorization requirements including coverage restrictions and step therapies
Or select your Insurance from the list below:
Radicava Prescribing Information
Radicava Prior Authorization Resources
Most recent state uniform prior authorization forms
Verified: Oct 24, 2024Arizona - Uniform Prior Authorization Form
Verified: Oct 24, 2024Colorado - Uniform Prior Authorization Form
Verified: Oct 24, 2024Hawaii - Uniform Prior Authorization Form
Verified: Oct 24, 2024Illinois - Uniform Prior Authorization Form
Verified: Oct 24, 2024Indiana - Uniform Prior Authorization Form
Verified: Oct 24, 2024Louisiana - Uniform Prior Authorization Form
Verified: Oct 24, 2024Minnesota - Uniform Prior Authorization Form
Verified: Oct 24, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Oct 24, 2024New Mexico - Uniform Prior Authorization Form
Verified: Oct 24, 2024Oregon - Uniform Prior Authorization Form
Verified: Oct 24, 2024Texas - Uniform Prior Authorization Form
Verified: Oct 05, 2024Washington - Uniform Prior Authorization Form
Verified: Oct 05, 2024Wisconsin - Uniform Prior Authorization Form
Benefits investigation
Reimbursement help (FRM)
Radicava Preferred Pharmacy
Radicava Financial Assistance Options
Copay savings program
Learn More
Overview
- Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
- A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
- Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
- Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
- May never be used with government insurance
How to sign up
- Cards may be downloadable digital cards or hard copies
- Some pharmacos offer debit cards with pre-loaded copay benefit
- Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
- Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Foundation programs
Learn More
Overview
- Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
- These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned
Patient benefit
- Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and copays) until the grant is exhausted
Patient eligibility
- Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.
How to sign up
- Patients submit proof of out-of-pocket drug costs to charities for reimbursement
Radicava PubMed™ News
Radicava Patient Education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
Other resources
Radicava FAQs
There's inadequate data on the developmental risk in pregnant women. Animal studies show adverse effects in pregnant rats and rabbits, including increased mortality, decreased growth, delayed sexual development, and altered behavior at clinically relevant doses. Most of these effects occurred at doses linked with maternal toxicity.
In the U.S. general population, estimated risks are 2-4% for major birth defects and 15-20% for miscarriage in recognized pregnancies. However, the background risk in ALS patients remains unknown.
In rats, edaravone administration throughout organogenesis resulted in reduced fetal weight and maternal toxicity at all doses tested. In rabbits, embryofetal death occurred at the highest dose, associated with maternal toxicity.
There's no data on edaravone in human milk or its effects on breastfed infants. However, it's known that edaravone and its metabolites are excreted in the milk of lactating rats.
Safety and effectiveness in pediatric patients have not been established for RADICAVA or RADICAVA ORS.
In clinical trials involving 184 ALS patients receiving RADICAVA, 53 were 65 or older, including 2 patients 75 or older. No overall differences in safety or effectiveness were observed compared to younger patients. However, some older individuals may exhibit greater sensitivity.
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available